baxdrostat/dapagliflozin / AstraZeneca - LARVOL DELTA

BaxDuo-Pacific: A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure (clinicaltrials.gov) - P3 | N=5000 | Recruiting | Sponsor: AstraZeneca | Trial completion date: Apr 2030 ➔ Dec 2029 | Trial primary completion date: Apr 2030 ➔ Dec 2029

Trial completion date • Trial primary completion date • Cardiovascular • Chronic Kidney Disease • Hypertension • Nephrology • Renal Disease

BaxDuo-Baltic: A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure. (clinicaltrials.gov) - P2 | N=218 | Not yet recruiting | Sponsor: AstraZeneca

New P2 trial • Cardiovascular • Chronic Kidney Disease • Hypertension • Nephrology • Renal Disease

A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure. (clinicaltrials.gov) - P3 | N=2455 | Active, not recruiting | Sponsor: AstraZeneca | Recruiting ➔ Active, not recruiting

Enrollment closed • Cardiovascular • Chronic Kidney Disease • Hypertension • Nephrology • Renal Disease